The study, by lead author Dr. James Yip, clinical professor of medicine at Weill Cornell Medicine and cardiologist at NewYork-Presbyterian/Weill Cornell Medical Center, and colleagues, explores the potential of calcium in nasal sprays. This is the latest in a series of studies demonstrating that Channel blocker etripamil as home treatment PSVT. Dr. Yip has received compensation for serving on the steering committee of Milestone Pharmaceuticals, the manufacturer of etripamil and sponsor of the trial.

PSVT patients repeatedly experience sudden, rapid heart rhythms caused by abnormal electrical activity in the heart’s upper ventricles. Although this condition is not usually life-threatening, it can be frightening and can cause shortness of breath, chest pain, dizziness, and fainting, leading to frequent emergency room visits. Treatment for PSVT often requires hospitalization to receive intravenous medication. Some patients undergo a procedure called cardiac ablation. In this surgery, doctors thread thin wires through blood vessels and use them to treat short circuits that cause abnormal heart rhythms.

Dr. Ip and colleagues previously showed that nearly two-thirds of PSVT patients who took one or more doses of the calcium channel blocker etripamil without consulting a doctor experienced symptom relief in an average of 17 minutes. The latest study builds on these findings, showing that etripamil is safe and effective under more realistic conditions in a larger patient population and may be safely used to treat multiple episodes of PSVT. It shows.

The new study enrolled 1,116 patients at 148 sites in the United States, Canada, and South America. As in previous studies, pre-test administration under medical supervision was not required. This included patients with a history of atrial fibrillation or atrial flutter, who had been excluded from previous studies. After self-administering the first dose, patients monitored their hearts with a home electrocardiogram monitor for 1 hour and were allowed to take additional doses as needed and self-treat up to four episodes of PSVT with etripamil. . Two-thirds of the patients experienced symptom relief within one hour, and the average time required for symptom relief was 17 minutes. Mild, temporary nasal symptoms, such as runny nose, nasal congestion or discomfort, and nosebleeds, were common after initial use of etripamil but became less common with subsequent use.